|
JP4944360B2
(ja)
|
2001-05-25 |
2012-05-30 |
アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） |
鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
|
|
DK2968443T3
(da)
|
2013-03-15 |
2021-12-06 |
Protagonist Therapeutics Inc |
Hepcidinanaloger og anvendelser deraf
|
|
US12383518B2
(en)
|
2013-11-03 |
2025-08-12 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Disulfide-masked pro-chelator compositions and methods of use
|
|
US11504346B2
(en)
|
2013-11-03 |
2022-11-22 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Redox-activated pro-chelators
|
|
PT3143037T
(pt)
|
2014-05-16 |
2021-09-24 |
Protagonist Therapeutics Inc |
Antagonistas peptídicos tioéter de integrina alfa4beta7
|
|
US9624268B2
(en)
|
2014-07-17 |
2017-04-18 |
Protagonist Therapeutics, Inc. |
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
|
|
KR20170108936A
(ko)
|
2014-10-01 |
2017-09-27 |
프로타고니스트 테라퓨틱스, 인코포레이티드 |
신규한 α4β7 펩타이드 단량체 및 이량체 길항제
|
|
EP3201217A4
(en)
|
2014-10-01 |
2018-07-18 |
Protagonist Therapeutics Inc. |
Novel cyclic monomer and dimer peptides having integrin antagonist activity
|
|
US10787490B2
(en)
|
2015-07-15 |
2020-09-29 |
Protaganist Therapeutics, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
US20190002503A1
(en)
|
2015-12-30 |
2019-01-03 |
Protagonist Therapeutics, Inc. |
Analogues of hepcidin mimetics with improved in vivo half lives
|
|
AU2017205633A1
(en)
*
|
2016-01-08 |
2018-08-16 |
La Jolla Pharmaceutial Company |
Methods of administering hepcidin
|
|
WO2017165676A1
(en)
|
2016-03-23 |
2017-09-28 |
Protagonist Therapeutics, Inc. |
METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS
|
|
CA3035234A1
(en)
*
|
2016-09-06 |
2018-03-15 |
La Jolla Pharmaceutical Company |
Methods of treating iron overload
|
|
JP2020502169A
(ja)
*
|
2016-12-19 |
2020-01-23 |
ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ |
ヘプシジンを投与する方法
|
|
WO2018128828A1
(en)
|
2016-12-23 |
2018-07-12 |
Bayer Healthcare Llc |
Novel hepcidin mimetics and uses thereof
|
|
US20200170971A1
(en)
*
|
2017-07-18 |
2020-06-04 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Disulfide-masked pro-chelator compositions and methods of use
|
|
EP3681900A4
(en)
|
2017-09-11 |
2021-09-08 |
Protagonist Therapeutics, Inc. |
OPIOID AGONIST PEPTIDES AND THEIR USES
|
|
EP3749345A4
(en)
*
|
2018-02-08 |
2022-04-06 |
Protagonist Therapeutics, Inc. |
CONJUGATED HEPCIDIN MIMETICS
|
|
TW202019948A
(zh)
|
2018-07-12 |
2020-06-01 |
美商領導醫療有限公司 |
介白素-23受體之肽抑制劑及其治療發炎疾病之用途
|
|
ES2934492T3
(es)
|
2018-12-13 |
2023-02-22 |
Global Blood Therapeutics Inc |
Inhibidores de ferroportina y métodos de uso
|
|
CA3139209A1
(en)
|
2019-05-07 |
2020-11-12 |
Bayer Aktiengesellschaft |
Masp inhibitory compounds and uses thereof
|
|
CN114341161A
(zh)
|
2019-07-10 |
2022-04-12 |
领导医疗有限公司 |
白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
|
|
US20210061872A1
(en)
*
|
2019-09-03 |
2021-03-04 |
Protagonist Therapeutics, Inc. |
Conjugated hepcidin mimetics
|
|
CN114761013A
(zh)
*
|
2019-09-27 |
2022-07-15 |
迪斯克医药公司 |
治疗骨髓纤维化和相关病症的方法
|
|
US20220372136A1
(en)
*
|
2019-09-27 |
2022-11-24 |
Disc Medicine, Inc. |
Methods for treating anemia of chronic disease
|
|
AU2021209086A1
(en)
|
2020-01-15 |
2022-08-04 |
Janssen Biotech, Inc. |
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
|
|
HRP20250769T1
(hr)
|
2020-01-15 |
2025-08-29 |
Janssen Biotech, Inc. |
Peptidni inhibitori receptora za interleukin-23 i njihova uporaba u liječenju upalnih bolesti
|
|
AU2021263818A1
(en)
|
2020-04-28 |
2022-11-03 |
Global Blood Therapeutics, Inc. |
Cycloalkyl pyrimidines as ferroportin inhibitors
|
|
EP4142732B1
(en)
|
2020-04-28 |
2026-04-22 |
Global Blood Therapeutics, Inc. |
Methods of use for pyrimidines as ferroportin inhibitors
|
|
EP4143197A1
(en)
|
2020-04-28 |
2023-03-08 |
Global Blood Therapeutics, Inc. |
Thieno pyrimidines as ferroportin inhibitors
|
|
WO2021231798A1
(en)
|
2020-05-13 |
2021-11-18 |
Disc Medicine, Inc. |
Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
|
|
CN111560051B
(zh)
*
|
2020-05-26 |
2022-11-25 |
大连工业大学 |
一种具有促铁吸收活性的虾源九肽及其应用
|
|
CN115997130A
(zh)
*
|
2020-07-02 |
2023-04-21 |
坦佩雷大学注册基金会 |
基于肾素的铁调素分析
|
|
IL299530A
(en)
*
|
2020-07-28 |
2023-02-01 |
Protagonist Therapeutics Inc |
Psidine is a conjugated mimetic
|
|
CN114252627A
(zh)
*
|
2020-09-24 |
2022-03-29 |
首都医科大学附属北京世纪坛医院 |
尿液铁调素及其多肽片段在过敏性疾病中的应用
|
|
AU2021383828A1
(en)
|
2020-11-20 |
2023-07-06 |
Janssen Pharmaceutica Nv |
Compositions of peptide inhibitors of interleukin-23 receptor
|
|
AU2022249095A1
(en)
*
|
2021-04-01 |
2023-10-12 |
Protagonist Therapeutics, Inc. |
Conjugated hepcidin mimetics
|
|
CA3220871A1
(en)
*
|
2021-06-14 |
2022-12-22 |
Protagonist Therapeutics, Inc. |
Hepcidin mimetics for treatment of hereditary hemochromatosis
|
|
WO2023288019A2
(en)
|
2021-07-14 |
2023-01-19 |
Janssen Biotech, Inc. |
Lipidated peptide inhibitors of interleukin-23 receptor
|
|
CN115703826B
(zh)
*
|
2021-08-03 |
2025-05-06 |
浙江大学 |
铁调素改造体及其应用
|
|
EP4587034A1
(en)
*
|
2022-09-15 |
2025-07-23 |
Migal Galilee Research Institute Ltd |
Site-specific activation of regulatory t cells
|
|
WO2025224128A1
(en)
|
2024-04-24 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Methods of treatment of iron overload associated diseases by administration hepcidin locally in the gut
|